🇺🇸 Teysuno in United States

32 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 28 March 2025 – 28 March 2026
• Total reports: 32

Most-reported reactions

1. Malignant Neoplasm Progression — 6 reports (18.75%)
2. Portal Vein Thrombosis — 6 reports (18.75%)
3. Aphasia — 3 reports (9.38%)
4. Cerebral Infarction — 3 reports (9.38%)
5. Eye Pain — 3 reports (9.38%)
6. Speech Disorder — 3 reports (9.38%)
7. Fatigue — 2 reports (6.25%)
8. Febrile Neutropenia — 2 reports (6.25%)
9. Metastases To Liver — 2 reports (6.25%)
10. Neoplasm Progression — 2 reports (6.25%)

Source database →

Frequently asked questions

Is Teysuno approved in United States?

Teysuno does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Teysuno in United States?

University of Edinburgh is the originator. The local marketing authorisation holder may differ — check the official source linked above.